Clinical Trial

Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control

Study acronym: RHIVIERA-02
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
RHIVIERA-02 trial is a placebo-controlled double-blinded two arm prospective phase II trial. This study will test the use of broadly neutralising antibodies (bNAbs) in participants, at primary HIV infection (PHI) and ART initiation.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-03-18; most recent amendment 2024-12-23.
Status change: Not Yet Recruiting → Recruiting 2024-04-12
Trial Details
NCT Number NCT05300035
Lead Sponsor ANRS, Emerging Infectious Diseases
Collaborators: Rockefeller University, Institut Pasteur
Conditions HIV/AIDS and Infections
Enrollment 69 participants
Start Date 2024-04-11
Primary Completion 2026-12-10 (estimated)
Study Completion 2028-12-10 (estimated)
Updated on ClinicalTrials.gov 2024-12-27